Evercore ISI says J&J loses market share in certain medtech segments

Enovis

22/01/2025 15:32

** Brokerage Evercore ISI says Johnson & Johnson's  JNJ.N 
Q4 medtech revenue was generally in line with estimates "with
strength in vision/hips offset by softer electrophysiology and
advanced surgery"
    ** J&J reports medtech Q4 revenue of $8.19 bln vs analysts'
estimates of $8.22 bln
    ** Brokerage says co's Q4 U.S. organic revenue growth of
2.1% in its electrophysiology (EP) segment is "soft", says share
losses to Boston Scientific  BSX.N  and Medtronic  MDT.N  from
their ongoing PFA launches "will be a focus"
    ** A pulsed field ablation system (PFA) is a type of heart
device to treat certain abnormal heart rhythm conditions
    ** Medical device maker Abbott  ABT.N  also reported Q4 
organic sales growth of 8.8% in its EP segment, which Evercore
says "seems to be holding slightly better" than J&J
    ** Brokerage adds J&J's soft growth in its spine segment
bodes well for other device makers Stryker  SYK.N , Zimmer
Biomet  ZBH.N , Enovis  ENOV.N  and Medtronic  
    ** J&J fell 7.7% in 2024 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))